H.C. Wainwright Reiterates Buy Rating on UroGen Pharma (URGN)

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $45.00 price target on UroGen Pharma (NASDAQ: URGN).

The analyst commented: "Yesterday, UroGen Pharma announced that the FDA had cleared the company's Investigational New Drug application (IND) for UGN-501, a next-generation oncolytic virus candidate. The IND clearance enables initiation of a planned Phase 1 study in patients with non-muscle invasive bladder cancer (NMIBC). The Phase 1 study is slated to start in 4Q26 and will evaluate the safety, tolerability, and feasibility of intravesical administration of UGN-501. NMIBC continues to present significant clinical challenges, particularly among patients whose disease recurs following standard treatment. Despite available therapies, recurrence rates remain substantial, underscoring the need for novel bladder-sparing therapeutic approaches. UroGen believes UGN-501's differentiated mechanism of action and local administration strategy may offer a promising new approach for addressing this unmet need. We reiterate our Buy rating and 12-month price target of $45."

For an analyst ratings summary and ratings history on UroGen Pharma click here. For more ratings news on UroGen Pharma click here.

Shares of UroGen Pharma closed at $38.03 yesterday.

You May Also Be Interested In

• Chevron signed an agreement with Iraq's Basra Oil Company to advance commercial negotiations for West Qurna 2
• Surya Oil & Gas faces lawsuit over alleged oral agreement
• Blue Star Gold closes $947,631 non-brokered private placement